Zhongguancun: Subsidiary company Shandong Huasu Amber Methotrexate API approved for listing.

Zhongguancun announced that its subsidiary Shandong Huasu Pharmaceutical Co., Ltd.'s "Metoprolol Succinate Active Pharmaceutical Ingredient" has passed the technical review of the Drug Evaluation Center of the National Medical Products Administration and has been granted the "Notice of Approval for Chemical Active Pharmaceutical Ingredient Market Application" issued by the National Medical Products Administration. The approval of this active pharmaceutical ingredient for the market provides a stable raw material source for the company's research on Metoprolol Succinate sustained-release capsules, which will have a positive impact on the company's business performance.